Penault-Llorca Frédérique, Abrial Catherine, Raoelfils Inès, Chollet Philippe, Cayre Anne, Mouret-Reynier Marie-Ange, Thivat Emilie, Mishellany Florence, Gimbergues Pierre, Durando Xavier
Centre Jean Perrin, Bureau de Recherche Clinique, Clermont-Ferrand Cedex 1, France.
Oncologist. 2008 Dec;13(12):1235-45. doi: 10.1634/theoncologist.2008-0073. Epub 2008 Dec 17.
The current study expands upon previous work using a database of 710 patients treated with neoadjuvant chemotherapy. First, we studied phenotypic characteristics of tumors before and after chemotherapy using the following factors: the mitotic index of the Scarff-Bloom-Richardson grade, Ki-67, cyclin D1, and cyclo-oxygenase-2. Second, the predictive value of these factors on response was assessed. Third, we measured the prognostic impact of these markers post-therapy in comparison with clinical and pathological responses according to the Chevallier and Sataloff classifications. Patients were treated using different neoadjuvant chemotherapy combinations, mainly in successive prospective phase II trials. They received a median number of six cycles (range, 1-9). After neoadjuvant chemotherapy, patients underwent surgery and radiotherapy. In cases of important residual disease, some received additional courses of chemotherapy. In addition, menopausal patients with hormone receptor-positive tumors received tamoxifen for 5 years. According to our analysis, we found significant variations before and after neoadjuvant chemotherapy only for cyclin D1 and the mitotic index. Concerning the predictive value of biomarkers for response, Ki-67 and the mitotic index were predictive on univariate analysis, both for objective clinical and pathological complete responses. Because these two factors were correlated, no multivariate analyses were conducted. We then assessed the prognostic impact of the biopathological factors. When the factors were measured before chemotherapy, all were prognostic. When evaluated after chemotherapy, the mitotic index, objective clinical response, and pathological complete response were prognostic. Because these factors were correlated, no multivariate model was done. The main clinical fact is that there were significant correlations between clinical and pathological responses and variations in the biological factors studied.
本研究在先前工作基础上进行了扩展,使用了一个包含710例接受新辅助化疗患者的数据库。首先,我们利用以下因素研究了化疗前后肿瘤的表型特征:斯卡夫-布鲁姆-理查森分级的有丝分裂指数、Ki-67、细胞周期蛋白D1和环氧化酶-2。其次,评估了这些因素对反应的预测价值。第三,根据谢瓦利埃和萨塔洛夫分类法,我们测量了这些标志物在治疗后与临床和病理反应相比的预后影响。患者接受了不同的新辅助化疗方案,主要是在连续的前瞻性II期试验中。他们接受的化疗周期中位数为6个(范围为1 - 9个)。新辅助化疗后,患者接受了手术和放疗。对于有重要残留病灶的病例,一些患者接受了额外的化疗疗程。此外,激素受体阳性肿瘤的绝经患者接受了5年的他莫昔芬治疗。根据我们的分析,我们发现新辅助化疗前后仅细胞周期蛋白D1和有丝分裂指数有显著变化。关于生物标志物对反应的预测价值,在单因素分析中,Ki-67和有丝分裂指数对客观临床和病理完全缓解均有预测作用。由于这两个因素相关,未进行多因素分析。然后我们评估了生物病理因素的预后影响。当在化疗前测量这些因素时,所有因素均具有预后意义。当在化疗后评估时,有丝分裂指数、客观临床反应和病理完全缓解具有预后意义。由于这些因素相关,未建立多因素模型。主要的临床事实是,临床和病理反应与所研究的生物学因素变化之间存在显著相关性。